Drug-induced acute pancreatitis (DIAP) is an inflammatory condition of the pancreas resulting from exposure to specific pharmacological agents. K85.30 specifically identifies cases where the drug-induced inflammation does not lead to persistent organ failure (defined as a Modified Marshall score of less than 2 for the respiratory, renal, or cardiovascular systems). The pathophysiology typically involves several mechanisms including hypersensitivity reactions, direct toxic effects, accumulation of toxic metabolites, or drug-induced hypertriglyceridemia. While over 500 medications have been implicated, it remains a diagnosis of exclusion after ruling out more common etiologies such as cholelithiasis and alcohol consumption. The clinical course is generally milder than other forms of pancreatitis when the offending agent is identified and discontinued promptly, though the condition can recur if the patient is re-exposed to the medication.
Identify and link the causative medication specifically.
Example: Patient presents with acute epigastric pain radiating to the back. Serum lipase elevated at 1200 U/L. Symptoms began four days after initiating Liraglutide for Type 2 Diabetes Mellitus. Diagnosis: Drug-induced acute pancreatitis due to Liraglutide. Plan: Discontinue Liraglutide, initiate aggressive IV hydration. ICD-10-CM: K85.30, T38.3X5A.
Billing Focus: Documentation must specify the causal relationship between the drug and the pancreatitis. Use an additional external cause code from categories T36 through T50 to identify the drug and specify the intent as an adverse effect.
Explicitly document the absence of organ failure.
Example: The patient exhibits no signs of respiratory distress, with SpO2 98 percent on room air. Creatinine is stable at 0.9 mg/dL. Blood pressure remains 120/70 mmHg without vasopressor support. This confirms the absence of renal, respiratory, or cardiovascular organ failure during this acute episode of drug-induced pancreatitis.
Billing Focus: The code K85.30 is specifically for cases where no organ failure is present. Documentation of stable vital signs and normal lab values for kidney and lung function supports the use of this specific fifth character.
Reference specific diagnostic criteria such as lipase levels and imaging.
Example: Acute abdominal pain consistent with pancreatitis. Lipase is 3 times the upper limit of normal. Contrast-enhanced CT scan shows peripancreatic stranding without necrosis or fluid collections. Patient was recently started on Azathioprine for Crohn disease, which is the suspected agent.
Billing Focus: Support the medical necessity of imaging (CPT 74176) and lab work (CPT 83690) by documenting the specific diagnostic thresholds met in the clinical note.
Distinguish between adverse effect and poisoning.
Example: The patient took their prescribed dose of Furosemide exactly as directed. The pancreatitis is an adverse effect of the correctly administered medication, not an intentional or accidental overdose.
Billing Focus: Ensuring the documentation reflects an adverse effect of a correctly prescribed and administered medication leads to the selection of T-codes ending in 5A (initial encounter for adverse effect), whereas poisoning would use different T-code endings.
Note the encounter type (Initial, Subsequent, Sequela).
Example: This is the initial hospital encounter for management of acute pancreatitis following the start of Valproic acid therapy for seizure disorder. Initial assessment and stabilization provided.
Billing Focus: While K85.30 itself does not require a 7th character, the associated T-code (e.g., T42.6X5A) must have a 7th character (A, D, or S) to denote the encounter phase.
Typically used for follow-up of acute pancreatitis where medication adjustments and monitoring of labs are required.
Used for stable patients returning for quick lab review or confirm cessation of causative agent.
Used for complex patients with multiple comorbidities where the drug-induced episode complicates other chronic conditions.
Primary imaging used to confirm inflammation and rule out necrosis or complications like pseudocysts.
Critical diagnostic test; elevation 3x upper limit is diagnostic of acute pancreatitis.
Secondary enzyme marker used alongside lipase for pancreatitis diagnosis.
Used when a patient is referred to a specialist for initial consultation regarding a drug-induced pancreatitis event.
Used to rule out other causes of abdominal pain such as peptic ulcer disease if drug-induced cause is uncertain.
Acute pancreatitis frequently requires hospitalization for IV fluids and monitoring.
Aggressive hydration is the standard of care for acute pancreatitis management.